Literature DB >> 8092818

Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations.

M K Hayden1, G I Koenig, G M Trenholme.   

Abstract

The effects of teicoplanin (8 micrograms/ml), ampicillin (64 micrograms/ml), imipenem (32 micrograms/ml), and gentamicin (4 micrograms/ml), alone and in combination, against 13 unique blood isolates of vancomycin-resistance (MIC for 90% of isolates tested [MIC90], 512 micrograms/ml), teicoplanin-susceptible (MIC90, 2.0 micrograms/ml), ampicillin-resistant (MIC90, 128 micrograms/ml), and non-beta-lactamase-producing Enterococcus facium (vancomycin-resistant enterococci [VRE] isolates) were evaluated by time-kill studies. All 13 isolates exhibited high-level resistance to streptomycin; 7 isolates exhibited high-level gentamicin resistance (HLGR). After 24 h of incubation, ampicillin (64 micrograms/ml) combined with gentamicin (4 micrograms/ml) was bactericidal against three of the VRE isolates that did not display HLGR. Synergy between ampicillin and gentamicin was not observed against these isolates. Teicoplanin (8 micrograms/ml) alone was bactericidal at 24 h against five of six VRE isolates that lacked HLGR, but was not bactericidal against any HLGR VRE isolate at that time point. The addition of ampicillin (64 micrograms/ml) or imipenem (32 micrograms/ml) to teicoplanin did not significantly enhance the killing of HLGR VRE isolates as a group (P = 0.335). However, there was a trend toward improved killing of some HLGR VRE isolates by teicoplanin plus imipenem. Vancomycin (32 micrograms/ml) combined with ampicillin (64 micrograms/ml) was neither bactericidal nor synergistic against HLGR VRE isolates. Overall, bactericidal activity was attainable against 7 of 13 VRE isolates at 24 h.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092818      PMCID: PMC188190          DOI: 10.1128/AAC.38.6.1225

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Synergy of penicillin and gentamicin against Enterococci.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

2.  Penicillin combined with gentamicin or streptomycin: synergism against enterococci.

Authors:  C Watanakunakorn
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

3.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

4.  Ribosomal resistance of clinical enterococcal to streptomycin isolates.

Authors:  G M Eliopoulos; B F Farber; B E Murray; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis.

Authors:  R C Moellering; B E Murray; S C Schoenbaum; J Adler; C B Wennersten
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

6.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

7.  Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism.

Authors:  D J Krogstad; T R Korfhagen; R C Moellering; C Wennersten; M N Swartz
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

8.  Antibiotic synergism in enterococcal endocarditis.

Authors:  J Carrizosa; D Kaye
Journal:  J Lab Clin Med       Date:  1976-07

9.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

10.  High-level resistance to gentamicin in clinical isolates of enterococci.

Authors:  B D Mederski-Samoraj; B E Murray
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

View more
  5 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Epidemiology and antibiotic treatment of infective endocarditis: an update.

Authors:  Bruno Hoen
Journal:  Heart       Date:  2006-11       Impact factor: 5.994

Review 3.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 4.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Medical treatment of endocarditis.

Authors:  Elias Abrutyn; Christopher H Cabell; Vance G Fowler; Bruno Hoen; José M Miro; Carlos A Mestres; Daniel J Sexton; G Ralph Corey
Journal:  Curr Infect Dis Rep       Date:  2007-07       Impact factor: 3.725

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.